Clasp Therapeutics to present preclinical data on novel T cell engager for p53 mutant tumors
- Clasp Therapeutics will present preclinical data on CLSP-1025, a T cell engager targeting p53 mutations.
- The presentation will occur at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Houston, Texas.
- CLSP-1025 targets the p53 R175H mutant peptide presented by HLA-A*02:01.
- The presentation is scheduled for November 8, 2024, from 9 a.m. to 7 p.m. CT.
Read more
First patient enrolled in phase I/IIa trial for HPV vaccine Lenti-HPV-07
- TheraVectys has enrolled the first patient in a Phase I/IIa trial for Lenti-HPV-07, targeting HPV-induced oropharyngeal and cervical cancers.
- The trial will involve 72 patients across two groups, focusing on safety, immunogenicity, and preliminary efficacy.
- Lenti-HPV-07 uses lentiviral vector technology, showing promising preclinical results in eliminating HPV-induced tumors.
- The trial includes dose escalation and expansion phases, with patients monitored for one year.
Read more
